<PAPER>
  <mode2 name="15888494_arathi" hasDoc="yes" version="1258"/>
  <TITLE>
    <s sid="1">Quantification of DNA and hemoglobin adducts of 3,4-epoxy-1,2-butanediol in rodents exposed to 3-butene-1,2-diol<CoreSc1 atype="GSC" type="Obj" conceptID="Obj1" novelty="None" advantage="None"/></s>
  </TITLE>
  <ABSTRACT>
    <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-1">
      <s sid="2">1,3-Butadiene (BD) is a confirmed rodent carcinogen and a suspect human carcinogen that forms mutagenic epoxide metabolites during biotransformation.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj2" novelty="None" advantage="None"/></s>
      <s sid="3">Species differences in the roles of individual DNA reactive intermediates in BD mutagenicity and carcinogenicity are not completely understood.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot1" novelty="None" advantage="None"/></s>
      <s sid="4">Evidence suggests that 1,2:3,4-diepoxybutane (DEB) is responsible for the mutagenic effect induced by exposures to low concentrations of BD in mice and that metabolites of 3-butene-1,2-diol (BD-diol) are involved in the mutagenicity at high exposures in both mice and rats.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac1" novelty="None" advantage="None"/></s>
      <s sid="5">Two reactive metabolites, 3,4-epoxy-1,2-butanediol (EB-diol) and hydroxymethylvinyl ketone (HMVK), are formed during the biotransformation of BD-diol and could potentially be involved in BD-diol associated mutagenicity.<CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp1" novelty="None" advantage="None"/></s>
      <s sid="6">To examine the role of EB-diol in BD-diol mutagenicity we have evaluated the dosimetry of N7-(2,3,4-trihydroxybutyl)guanine (THB-Gua) and N-(2,3,4-trihydroxybutyl)valine (THB-Val) in female B6C3F1 mice and female F344 rats exposed by inhalation to 0, 6, 18 and 36 p.p.m. BD-diol for 4 weeks (6 h/day &#215; 5 days/week).<CoreSc1 atype="GSC" type="Goa" conceptID="Goa1" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Exp" conceptID="Exp1" novelty="None" advantage="None"/></s>
      <s sid="7">Results showed higher levels of both THB-Gua and THB-Val in mice than in rats.<CoreSc1 atype="GSC" type="Res" conceptID="Res1" novelty="None" advantage="None"/></s>
      <s sid="8">An evaluation of THB-Gua adducts showed virtually no differences between liver and lung for either species, suggesting that EB-diol is stable and is freely circulated.<CoreSc1 atype="GSC" type="Res" conceptID="Res2" novelty="None" advantage="None"/></s>
      <s sid="9">The data also indicated that THB adduct formation began to plateau around 18 p.p.m. in both species.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs1" novelty="None" advantage="None"/></s>
      <s sid="10">Most importantly, the shape of the dose&#8211;response curve for THB adduct formation mimicked the one observed for hypoxanthine-guanine phosphoribosyltransferase (Hprt) mutation frequency.<CoreSc1 atype="GSC" type="Res" conceptID="Res3" novelty="None" advantage="None"/></s>
      <s sid="11">This showed that THB adducts, which are not thought to be responsible for causing the mutations, are good quantitative indicators of mutagenicity in rodents exposed to BD-diol.<CoreSc1 atype="GSC" type="Con" conceptID="Con1" novelty="None" advantage="None"/></s>
      <s sid="12">Although the potential contribution of HMVK still needs to be evaluated, the data suggest that EB-diol is responsible, at least in part, for BD-diol associated mutagenicity in rodents.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot2" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Con" conceptID="Con2" novelty="None" advantage="None"/></s>
    </p>
  </ABSTRACT>
  <BODY>
    <SEC>
      <TITLE>Introduction</TITLE>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-2">
        <s sid="13">1,3-Butadiene (BD) is an important commercial chemical and environmental pollutant that causes exposure-related increases of various cancers in mice and rats.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj3" novelty="None" advantage="None"/></s>
        <s sid="14">Mice are the more sensitive species and females the more sensitive sex (<xref class="xref-bibr" href="#ref-1" rid="xref-ref-1-1">1</xref>&#8211;<xref class="xref-bibr" href="#ref-5" rid="xref-ref-5-1">5</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac2" novelty="None" advantage="None"/></s>
        <s sid="15">Female B6C3F1 mice exposed via inhalation to BD concentrations as low as 6.25 p.p.m. developed lung tumors (<xref class="xref-bibr" href="#ref-2" rid="xref-ref-2-2">2</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac3" novelty="None" advantage="None"/></s>
        <s sid="16">Although different interpretations of the results exist, epidemiology studies show an increase in the incidence of leukemia in synthetic rubber production workers exposed to BD (<xref class="xref-bibr" href="#ref-6" rid="xref-ref-6-1">6</xref>) and an increase in lymphohematopoietic cancers in BD production workers (<xref class="xref-bibr" href="#ref-7" rid="xref-ref-7-1">7</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac4" novelty="None" advantage="None"/></s>
        <s sid="17">The National Toxicology Program classifies BD as a known human carcinogen (<xref class="xref-bibr" href="#ref-8" rid="xref-ref-8-1">8</xref>), the International Agency for the Research of Cancer classifies BD as a probable human carcinogen (<xref class="xref-bibr" href="#ref-9" rid="xref-ref-9-1">9</xref>) and BD is classified by the US Environmental Protection Agency as carcinogenic to humans by inhalation (<xref class="xref-bibr" href="#ref-10" rid="xref-ref-10-1">10</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac5" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-3">
        <s sid="18">BD biotransformation is complex and involves several pathways.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac6" novelty="None" advantage="None"/></s>
        <s sid="19">Of particular interest in the current study is the 3-butene-1,2-diol (BD-diol) metabolic pathway (<xref class="xref-fig" href="#F1" rid="xref-fig-1-1">Scheme 1</xref>).<CoreSc1 atype="GSC" type="Obj" conceptID="Obj4" novelty="None" advantage="None"/></s>
        <s sid="20">BD is initially metabolized via cytochrome P450 (CYP450) to 1,2-epoxy-3-butene (EB) (<xref class="xref-bibr" href="#ref-11" rid="xref-ref-11-1">11</xref>&#8211;<xref class="xref-bibr" href="#ref-13" rid="xref-ref-13-1">13</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac7" novelty="None" advantage="None"/></s>
        <s sid="21">BD-diol is then formed by the subsequent hydrolysis of EB by epoxide hydrolase (EH) (<xref class="xref-bibr" href="#ref-11" rid="xref-ref-11-2">11</xref>&#8211;<xref class="xref-bibr" href="#ref-14" rid="xref-ref-14-1">14</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac8" novelty="None" advantage="None"/></s>
        <s sid="22">BD-diol is metabolized by CYP450 to form hydroxymethylvinyl ketone (HMVK) (<xref class="xref-bibr" href="#ref-15" rid="xref-ref-15-1">15</xref>) or 3,4-epoxy-1,2-butanediol (EB-diol) (<xref class="xref-bibr" href="#ref-11" rid="xref-ref-11-3">11</xref>,<xref class="xref-bibr" href="#ref-13" rid="xref-ref-13-3">13</xref>,<xref class="xref-bibr" href="#ref-16" rid="xref-ref-16-1">16</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac9" novelty="None" advantage="None"/></s>
        <s sid="23">BD-diol can also be metabolized by alcohol dehydrogenase (ADH) to 2-hydroxy-3-butenal (HBAL), which may spontaneously rearrange to form HMVK (<xref class="xref-bibr" href="#ref-17" rid="xref-ref-17-1">17</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac10" novelty="None" advantage="None"/></s>
        <s sid="24">HMVK reacts with glutathione via glutathione-S-transferase (GST) to eventually form mercapturic acids (<xref class="xref-bibr" href="#ref-18" rid="xref-ref-18-1">18</xref>&#8211;<xref class="xref-bibr" href="#ref-22" rid="xref-ref-22-1">22</xref>) including 1,2-dihydroxy-4-(N-acetylcysteinyl)butane (MI), the primary mercapturic acid metabolite found in the urine of humans exposed to BD (<xref class="xref-bibr" href="#ref-19" rid="xref-ref-19-2">19</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac11" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-5">
        <s sid="25">Several reactive intermediates are formed during BD metabolism.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac12" novelty="None" advantage="None"/></s>
        <s sid="26">Although DEB, EB and EB-diol are known mutagens (<xref class="xref-bibr" href="#ref-23" rid="xref-ref-23-1">23</xref>,<xref class="xref-bibr" href="#ref-24" rid="xref-ref-24-1">24</xref>), the role of these epoxides in BD mutagenesis and carcinogenesis is not fully understood.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot3" novelty="None" advantage="None"/></s>
        <s sid="27">By evaluating the induction of Hprt mutations in rodents exposed to relevant concentrations of BD, EB, DEB and BD-diol, Walker et al. (<xref class="xref-bibr" href="#ref-25" rid="xref-ref-25-1">25</xref>) proposed that DEB is responsible for mutagenicity in mice exposed to low levels of BD, while metabolites of BD-diol play a significant role in the mutagenic response in mice and rats exposed to higher concentrations of BD.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac13" novelty="None" advantage="None"/></s>
        <s sid="28">EB is not thought to play a major role in mutagenicity in either species (<xref class="xref-bibr" href="#ref-25" rid="xref-ref-25-2">25</xref>,<xref class="xref-bibr" href="#ref-26" rid="xref-ref-26-1">26</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac14" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-6">
        <s sid="29">In addition to being implicated in the mutagenicity of BD, the BD-diol pathway is important for several reasons.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac15" novelty="None" advantage="None"/></s>
        <s sid="30">First, exposure to BD-diol via inhalation causes an increase in Hprt mutation frequency in both mice and rats (<xref class="xref-bibr" href="#ref-25" rid="xref-ref-25-3">25</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac16" novelty="None" advantage="None"/></s>
        <s sid="31">Second, intraperitoneal administration of a high dose of BD-diol is hepatotoxic in rats (<xref class="xref-bibr" href="#ref-27" rid="xref-ref-27-1">27</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac17" novelty="None" advantage="None"/></s>
        <s sid="32">Third, BD-diol is a precursor to MI, an important urinary metabolite in humans exposed to BD (<xref class="xref-bibr" href="#ref-19" rid="xref-ref-19-3">19</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac18" novelty="None" advantage="None"/></s>
        <s sid="33">Fourth, BD-diol is a major metabolite of BD in single-pass liver perfusion experiments conducted in both mice and rats (<xref class="xref-bibr" href="#ref-28" rid="xref-ref-28-1">28</xref>) and is present in the urine of rodents exposed to BD (<xref class="xref-bibr" href="#ref-25" rid="xref-ref-25-4">25</xref>,<xref class="xref-bibr" href="#ref-29" rid="xref-ref-29-1">29</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac19" novelty="None" advantage="None"/></s>
        <s sid="34">Finally, as previously shown, the metabolism of BD-diol yields two reactive compounds.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac20" novelty="None" advantage="None"/></s>
        <s sid="35">EB-diol is a known mutagen (<xref class="xref-bibr" href="#ref-23" rid="xref-ref-23-2">23</xref>,<xref class="xref-bibr" href="#ref-24" rid="xref-ref-24-2">24</xref>), while HMVK is expected to be mutagenic based on comparisons with other &#945;,&#946;-unsaturated carbonyls (<xref class="xref-bibr" href="#ref-30" rid="xref-ref-30-1">30</xref>) and because it reacts with DNA in vitro to form potentially promutagenic exocyclic DNA adducts (<xref class="xref-bibr" href="#ref-31" rid="xref-ref-31-1">31</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac21" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-7">
        <s sid="36">The primary goal of the current study was to characterize the dose&#8211;response relationships between direct exposures of mice and rats to BD-diol and the formation of an N7-guanine DNA adduct and an N-terminal valine adduct of hemoglobin derived from the in vivo conversion of BD-diol to EB-diol.<CoreSc1 atype="GSC" type="Goa" conceptID="Goa2" novelty="None" advantage="None"/></s>
        <s sid="37">This objective was accomplished by quantifying N7-(2,3,4-trihydroxybutyl)guanine (THB-Gua; <xref class="xref-fig" href="#F2" rid="xref-fig-2-1">Figure 1a</xref>) and N-(2,3,4-trihydroxybutyl)valine (THB-Val; <xref class="xref-fig" href="#F2" rid="xref-fig-2-2">Figure 1b</xref>) in female B6C3F1 mice and female F344 rats exposed via inhalation to 0, 6, 18 and 36 p.p.m. BD-diol (6 h/day &#215; 5 days/week &#215; 4 weeks).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp2" novelty="None" advantage="None"/></s>
        <s sid="38">In this fashion, we evaluated tissue and species-specific differences in DNA adduct formation in liver (a major site of metabolism) and lung (a target organ for BD-induced cancer in the mouse) of BD-diol exposed mice and rats.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj5" novelty="None" advantage="None"/></s>
        <s sid="39">Species differences were also evaluated for hemoglobin adducts.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj6" novelty="None" advantage="None"/></s>
        <s sid="40">In addition, DNA and hemoglobin adduct formation were compared with the Hprt mutant frequency data for concurrently exposed rodents to understand the role of EB-diol in mutagenicity occurring via the BD-diol pathway.<CoreSc1 atype="GSC" type="Met" conceptID="Met1" novelty="None" advantage="None"/></s>
      </p>
    </SEC>
    <SEC>
      <TITLE>Materials and methods</TITLE>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Chemicals</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-9">
        <s sid="41">Lysis buffer, phenol&#8211;H<sub>2</sub>O&#8211;chloroform and Proteinase K were purchased from Applied Biosystems (Foster City, CA); RNase A from Sigma Aldrich (St Louis, MO); pentafluorophenylisothiocyanate (PFPITC) from Fluka (Milwaukee, WI); &#177; BD-diol from Aldrich Chemical (Milwaukee).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp3" novelty="None" advantage="None"/></s>
        <s sid="42">All other chemicals were purchased from common vendors.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp4" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Animals and BD-diol exposures</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-10">
        <s sid="43">The exposure protocol has been presented in detail elsewhere (<xref class="xref-bibr" href="#ref-25" rid="xref-ref-25-5">25</xref>).<CoreSc1 atype="GSC" type="Met" conceptID="Met2" novelty="None" advantage="None"/></s>
        <s sid="44">Briefly, 4&#8211;5 week old female B6C3F1 mice and female F344 rats were exposed via inhalation to various concentrations of BD-diol vapor using whole-body exposure chambers (6 h/day &#215; 5 days/week &#215; 4 weeks).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp5" novelty="None" advantage="None"/></s>
        <s sid="45">Two separate series of exposures were performed using an identical protocol.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp6" novelty="None" advantage="None"/></s>
        <s sid="46">In the first series, rodents were exposed to 0, 6 or 18 p.p.m. BD-diol, whereas in the second series another group of rodents was exposed to 0 or 36 p.p.m. BD-diol.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp7" novelty="None" advantage="None"/></s>
        <s sid="47">BD-diol exposure atmospheres were monitored using two techniques, a real time hydrocarbon analyzer and an integrated sample to verify the response of the hydrocarbon analyzer relative to actual BD-diol concentrations.<CoreSc1 atype="GSC" type="Met" conceptID="Met3" novelty="None" advantage="None"/></s>
        <s sid="48">The hydrocarbon analyzer was a real-time flame ionization detector (Model 300H, Analytical Instruments, Irvine, CA) calibrated against a certified propane standard.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj7" novelty="None" advantage="None"/></s>
        <s sid="49">This instrument gave real-time data for maintaining the stability of the exposure concentrations and for assessing the rise and decline of BD-diol chamber concentrations.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp8" novelty="None" advantage="None"/></s>
        <s sid="50">The integrated samples were collected in 30 ml glass impingers containing 20 ml of purified H<sub>2</sub>O. Impingers were placed on ice and samples were collected at a flow rate of 0.3 liters per min for 30 min.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp9" novelty="None" advantage="None"/></s>
        <s sid="51">Periodically, back-up impingers were collected to verify the absence of sample break-through in the front trap.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp10" novelty="None" advantage="None"/></s>
        <s sid="52">After collection, the samples were immediately analyzed by gas chromatography/flame ionization detection.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp11" novelty="None" advantage="None"/></s>
        <s sid="53">Stock standards were made from aliquots of BD-diol purchased for animal exposures, and calibration solutions were created in ddH<sub>2</sub>O and spanned from 7.8&#8211;125 &#956;g/ml.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp12" novelty="None" advantage="None"/></s>
        <s sid="54">BD-diol atmospheres were compared with five-point calibration curves that spanned the exposure range required to measure with accuracy the lower and upper ends of the BD-diol exposure concentrations used in rodent inhalation studies.<CoreSc1 atype="GSC" type="Met" conceptID="Met4" novelty="None" advantage="None"/></s>
        <s sid="55">At no time did the BD-diol exposure atmosphere concentration exceed the upper calibration concentration.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp13" novelty="None" advantage="None"/></s>
        <s sid="56">Analysis of exposure atmospheres by GC and a flame ionization detector revealed no detectable impurities, attesting to both the stability of the exposure atmosphere and the lack of detectable impurities in the reference BD-diol (certified as &gt;99% pure).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp14" novelty="None" advantage="None"/></s>
        <s sid="57">Actual concentrations of BD-diol were 6.0 &#177; 0.7, 16.5 &#177; 0.7 and 33.4 &#177; 4.7 p.p.m., corresponding to nominal concentrations of 6, 18 and 36 p.p.m. Blood and tissues were collected within 2 h after the cessation of final BD-diol exposure.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp15" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">DNA isolation</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-11">
        <s sid="58">Note: centrifugation steps were performed at 4&#176;C.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp16" novelty="None" advantage="None"/></s>
        <s sid="59">Approximately 0.5 g tissue was weighed and homogenized in 8 ml cold phosphate buffered saline (PBS) buffer (1&#215;) (if smaller amounts of tissue were used, reagent volumes were adjusted accordingly).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp17" novelty="None" advantage="None"/></s>
        <s sid="60">This homogenate was transferred to a 50 ml sample tube and centrifuged for 10 min at 1500 g.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp18" novelty="None" advantage="None"/></s>
        <s sid="61">After discarding the supernatant, the pellet was resuspended in 8 ml of lysis buffer (1&#215;).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp19" novelty="None" advantage="None"/></s>
        <s sid="62">To this, 125 &#956;l of Proteinase K (66 U) was added and the solution rotated overnight at 4&#176;C and 5 &#956;l of phenol&#8211;H<sub>2</sub>O&#8211;chloroform was introduced, and the mixture centrifuged for 10 min at 1800 g.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp20" novelty="None" advantage="None"/></s>
        <s sid="63">The top phase was transferred to a new 50 ml sample tube and the extraction repeated.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp21" novelty="None" advantage="None"/></s>
        <s sid="64">After transferring the top phase to a new 50 ml sample tube, 5 ml SEVAG (98:2 chloroform:isoamyl alcohol v/v) was added, and the mixture centrifuged for 5 min at 1800 g.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp22" novelty="None" advantage="None"/></s>
        <s sid="65">DNA was precipitated by adding 300 &#956;l of NaCl (5 M) and 10 ml of 100% ethanol followed by gentle mixing.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp23" novelty="None" advantage="None"/></s>
        <s sid="66">The solution was centrifuged for 10 min at 1800 g and the supernatant discarded.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp24" novelty="None" advantage="None"/></s>
        <s sid="67">To the pellet, 10 &#956;l of 70% ethanol was added, centrifugation repeated, and the supernatant discarded.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp25" novelty="None" advantage="None"/></s>
        <s sid="68">The pellet was resuspended in 4 ml of PBS (1&#215;) and rotated overnight at 4&#176;C and 12 &#956;l of RNase A (1.3 U) was added, and the solution incubated for 30 min at 37&#176;C.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp26" novelty="None" advantage="None"/></s>
        <s sid="69">To this, 1 ml of ddH<sub>2</sub>O and 6.5 ml of 100% ethanol were added, the solution was then mixed and centrifuged for 10 min at 1800 g.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp27" novelty="None" advantage="None"/></s>
        <s sid="70">The supernatant was discarded, the pellet resuspended in 10 ml of 70% ethanol, and the mixture centrifuged for 10 min at 1800 g.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp28" novelty="None" advantage="None"/></s>
        <s sid="71">After removing the supernatant, the pellet was resuspended in 0.5 ml of ddH<sub>2</sub>O, placed at 4&#176;C for 1 h and then stored until use at &#8211;80&#176;C.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp29" novelty="None" advantage="None"/></s>
        <s sid="72">A small aliquot was used for the initial determination of DNA concentration by UV spectrophotometry.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp30" novelty="None" advantage="None"/></s>
        <s sid="73">Final DNA concentration was determined using a PicoGreen dsDNA quantification kit (Molecular Probes, Eugene, OR).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp31" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">THB-Gua sample preparation</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-12">
        <s sid="74">DNA (250&#8211;500 &#956;g as determined by initial measurements using UV spectrophotometry) and internal standard [(<sup>13</sup>C<sub>4</sub>)-THB-Gua] were combined in a sample tube and brought to a final volume of 1 ml with HPLC grade H<sub>2</sub>O. The sample was incubated at &#8764;95&#176;C for 30 min and subsequently cooled on ice for 5 min.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp32" novelty="None" advantage="None"/></s>
        <s sid="75">To the sample 1 ml of HPLC grade H<sub>2</sub>O was added and the mixture filtered by centrifugation for 2 h at 5000 g using a Centricon-10 filter.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp33" novelty="None" advantage="None"/></s>
        <s sid="76">Following filtration, the sample was dried by centrifugal lyophilization and resuspended in 50 &#956;l of HPLC grade H<sub>2</sub>O. The sample was then transferred to a sample vial and stored at &#8722;80&#176;C until analysis.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp34" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Quantification of THB-Gua</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-13">
        <s sid="77">Samples were analyzed by liquid chromatography&#8211;tandem mass spectrometry (LC-MS/MS) using a Finnigan Surveyor micro-LC system coupled with a Finnigan TSQ Quantum triple-quadrupole mass spectrometer (Thermo Electron, San Jose, CA).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp35" novelty="None" advantage="None"/></s>
        <s sid="78">Separation of THB-Gua from unmodified bases was performed on an Aquasil C18 column (5 &#956;m; 2.1 mm &#215; 150 mm) (Thermo Electron) preceded by a guard cartridge, using HPLC grade H<sub>2</sub>O with 0.1% acetic acid (solvent A) and acetonitrile with 0.1% acetic acid (solvent B).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp36" novelty="None" advantage="None"/></s>
        <s sid="79">Injection volumes of 10 &#956;l were used.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp37" novelty="None" advantage="None"/></s>
        <s sid="80">The following gradient was used: 0&#8594;1 min, 100% A; 1&#8594;10 min, 100&#8594;85% A; 10&#8594;15 min, 85&#8594;20% A; 15&#8594;25 min, 100% A. The flowrate throughout the analysis was 200 &#956;l/min.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp38" novelty="None" advantage="None"/></s>
        <s sid="81">MS parameters were as follows: polarity, positive; spray voltage, 4500 V; sheath gas, 47 (arbitrary unit); auxiliary gas, 5 (arbitrary unit); capillary temp, 350&#176;C; source CID, 10 V; collision energy, 22 V; collision gas, 1.5 mTorr.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp39" novelty="None" advantage="None"/></s>
        <s sid="82">Adducts were detected using MS/MS with selected reaction monitoring (SRM) of m/z 256&#8594;152, corresponding to the loss of the THB side-chain (<xref class="xref-bibr" href="#ref-32" rid="xref-ref-32-1">32</xref>).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp40" novelty="None" advantage="None"/></s>
        <s sid="83">The ratio of the analyte peak area to that of the internal standard, measured by SRM of m/z 260&#8594;156, was used to quantify the adduct.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp41" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Globin isolation</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-14">
        <s sid="84">Note: centrifugation steps were performed at 4&#176;C.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp42" novelty="None" advantage="None"/></s>
        <s sid="85">Globin was isolated by the method of Mowrer et al. (<xref class="xref-bibr" href="#ref-33" rid="xref-ref-33-1">33</xref>), with slight modifications for the isolation of mouse globin (<xref class="xref-bibr" href="#ref-34" rid="xref-ref-34-1">34</xref>).<CoreSc1 atype="GSC" type="Met" conceptID="Met5" novelty="None" advantage="None"/></s>
        <s sid="86">Packed red blood cells were mixed and lysed with 1 ml ddH<sub>2</sub>O. After complete mixing, acid propanol (9 ml for mouse globin and 6 ml for rat globin) was added and the solution vortexed.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp43" novelty="None" advantage="None"/></s>
        <s sid="87">The solution was then centrifuged for 30 min at 1500 g.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp44" novelty="None" advantage="None"/></s>
        <s sid="88">The supernatant was carefully transferred into a fresh tube, ethyl acetate added (6 ml for mouse and 4 ml for rat) and the solution vortexed until the globin precipitated.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp45" novelty="None" advantage="None"/></s>
        <s sid="89">The sample was then centrifuged for 5 min at 1500 g and the supernatant discarded.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp46" novelty="None" advantage="None"/></s>
        <s sid="90">The pellet was resuspended in 4 ml ethyl acetate and the centrifugation step repeated.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp47" novelty="None" advantage="None"/></s>
        <s sid="91">These steps were repeated until a colorless supernatant was obtained.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp48" novelty="None" advantage="None"/></s>
        <s sid="92">The step was then repeated using n-pentane.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp49" novelty="None" advantage="None"/></s>
        <s sid="93">The resulting pellet was dried and stored at &#8722;80&#176;C.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp50" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">THB-Val sample preparation</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-15">
        <s sid="94">The globin was derivatized based on a modified Edman degradation (<xref class="xref-bibr" href="#ref-35" rid="xref-ref-35-1">35</xref>).<CoreSc1 atype="GSC" type="Met" conceptID="Met6" novelty="None" advantage="None"/></s>
        <s sid="95">For this, 2&#8211;5 mg mouse globin or 6&#8211;10 mg rat globin was dissolved in 1.5 ml formamide and 30 &#956;l of 1 M NaOH added.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp51" novelty="None" advantage="None"/></s>
        <s sid="96">To this, 20 &#956;l of PFPITC was added and the reaction mixture incubated at room temperature overnight with shaking.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp52" novelty="None" advantage="None"/></s>
        <s sid="97">Derivatized THB-Val internal standard [THB-(<sup>13</sup>C<sub>5</sub>)-Val-PFPTH] was added and the samples incubated for an additional 1.5 h at 45&#176;C.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp53" novelty="None" advantage="None"/></s>
        <s sid="98">The sample was extracted 3 times with 3 ml diethylether and dried by centrifugal lyophilization.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp54" novelty="None" advantage="None"/></s>
        <s sid="99">The residue was resuspended in 1 ml of 0.1 M Na<sub>2</sub>CO<sub>3</sub> and applied to a 200 mg Extract-Clean C<sub>18</sub> solid phase extraction column (Alltech Associates, Deerfield, IL) pre-equilibrated with 50:50 formamide:ddH<sub>2</sub>O (v/v).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp55" novelty="None" advantage="None"/></s>
        <s sid="100">After sample application, the column was washed with 1 ml of ddH<sub>2</sub>O and the adduct containing fraction eluted with 3 ml acetonitrile prior to being dried by centrifugal lyophilization.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp56" novelty="None" advantage="None"/></s>
        <s sid="101">The sample was extracted by adding 1 ml of 60% methanol and 2 ml of hexane.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp57" novelty="None" advantage="None"/></s>
        <s sid="102">The aqueous layer was removed and dried by centrifugal lyophilization prior to acetylation by adding 188 &#956;l acetonitrile, 32.5 &#956;l triethylamine, 32.5 &#956;l acetic anhydride and incubating for 30 min at room temperature.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp58" novelty="None" advantage="None"/></s>
        <s sid="103">It was subsequently dried by centrifugal lyophilization, resuspended in 3 ml of n-pentane and washed with 2 ml of 60% methanol.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp59" novelty="None" advantage="None"/></s>
        <s sid="104">The n-pentane layer was evaporated, the sample resuspended in 50 &#956;l toluene, placed in a sample vial and stored at &#8211;80&#176;C until analysis.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp60" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">THB-Val quantification</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-16">
        <s sid="105">Samples were analyzed by GC&#8211;tandem mass spectrometry (GC-MS/MS) using a Trace GC2000 coupled with a Finnigan TSQ 7000 triple-quadrupole mass spectrometer (Thermo Quest Finnigan, San Jose, CA).The analysis was performed with electron-capture negative chemical ionization (ECNCI) using methane as the reagent gas (3 &#215; 10<sup>&#8722;5</sup> mbar).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp61" novelty="None" advantage="None"/></s>
        <s sid="106">Sample volumes of 2 &#956;l were injected by an AS2000 autosampler (Thermo Quest Finnigan) in the splitless mode at a 270&#176;C injector temperature.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp62" novelty="None" advantage="None"/></s>
        <s sid="107">Separation was performed on an Alltech EC-5 column (30 m &#215; 0.32 mm, 1.0 &#956;m film thickness) (Alltech Associates) with 10 &#936; helium head pressure.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp63" novelty="None" advantage="None"/></s>
        <s sid="108">The capillary column temperature was programmed to increase from 100&#176;C to 320&#176;C at a rate of 10&#176;C/min.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp64" novelty="None" advantage="None"/></s>
        <s sid="109">The TSQ 7000 was operated using the following parameters: polarity, negative; electron energy, 70 V; source pressure, 3.5 Torr; ion source temperature, 150&#176;C; emission current, 500 &#956;A; collision energy, 10 V; collision gas, 2.5 mTorr.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp65" novelty="None" advantage="None"/></s>
        <s sid="110">Adducts were measured by MS/MS using SRM of m/z 534&#8594;303.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp66" novelty="None" advantage="None"/></s>
        <s sid="111">m/z 534 corresponds to the loss of [HF]<sup>&#8722;</sup> from the derivatized adduct and m/z 303 corresponds to the loss of the THB side-chain from the adduct (<xref class="xref-bibr" href="#ref-36" rid="xref-ref-36-1">36</xref>).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp67" novelty="None" advantage="None"/></s>
        <s sid="112">Adduct quantification was performed by comparing analyte peak area with that of the internal standard (SRM of m/z 539&#8594;308).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp68" novelty="None" advantage="None"/></s>
      </p>
    </SEC>
    <SEC>
      <TITLE>Results</TITLE>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Dosimetry of THB-Gua</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-17">
        <s sid="113">Because of the stereochemical characteristics of EB-diol, THB-Gua exists as two racemates and two meso isomers (<xref class="xref-bibr" href="#ref-37" rid="xref-ref-37-1">37</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac22" novelty="None" advantage="None"/></s>
        <s sid="114">An LC-MS/MS chromatogram from the liver of female F344 rats exposed to 36 p.p.m. BD-diol clearly shows a peak containing the racemic mixture of enantiomers as well as an overlapping peak corresponding to meso THB-Gua (<xref class="xref-fig" href="#F3" rid="xref-fig-3-1">Figure 2</xref>).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs2" novelty="None" advantage="None"/></s>
        <s sid="115">Although racemic THB-Gua internal standard was used, the levels of racemic and meso adduct were combined and presented as total THB-Gua.<CoreSc1 atype="GSC" type="Met" conceptID="Met7" novelty="None" advantage="None"/></s>
        <s sid="116">The limit of detection, defined as the amount of standard yielding a signal/noise (S/N) of &#8805; 3, was &#8764;3.5 fmol of pure standard injected on column.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs3" novelty="None" advantage="None"/></s>
        <s sid="117">A representative calibration curve is provided in <xref class="xref-fig" href="#F4" rid="xref-fig-4-1">Figure 3</xref>.<CoreSc1 atype="GSC" type="Met" conceptID="Met8" novelty="None" advantage="None"/></s>
        <s sid="118">The smallest amount of adduct measured in samples from BD-diol exposed rodents was &#8764;33 fmol injected on column.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs4" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-20">
        <s sid="119">Summary data for THB-Gua formation in rodents exposed to BD-diol is presented in <xref class="xref-table" href="#T1" rid="xref-table-wrap-1-1">Table I</xref>.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs5" novelty="None" advantage="None"/></s>
        <s sid="120">Several statistical comparisons were performed with these data using Student's t-test (&#945; = 0.05).<CoreSc1 atype="GSC" type="Met" conceptID="Met9" novelty="None" advantage="None"/></s>
        <s sid="121">A comparison to determine if a statistically significant difference in mean adduct levels existed between species showed that mice have a greater amount of adduct than rat in both the liver and the lung at 6 and 18 p.p.m. BD-diol.<CoreSc1 atype="GSC" type="Res" conceptID="Res4" novelty="None" advantage="None"/></s>
        <s sid="122">A 2.4-fold greater amount of THB-Gua was present in mouse liver and a 2.3-fold increase in mouse lung was observed for rodents exposed to 6 p.p.m. BD-diol, whereas at 18 p.p.m. a 2.3-fold increase existed for mouse liver and 3.5-fold increase for mouse lung.<CoreSc1 atype="GSC" type="Res" conceptID="Res5" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-27">
        <s sid="123">A second comparison was performed to determine if there were tissue differences in the levels of adducts.<CoreSc1 atype="GSC" type="Goa" conceptID="Goa3" novelty="None" advantage="None"/></s>
        <s sid="124">Our data showed only one instance of a statistical difference between tissues, with significantly higher levels of adducts found in liver than lung of rats exposed to 18 p.p.m. BD-diol.<CoreSc1 atype="GSC" type="Res" conceptID="Res6" novelty="None" advantage="None"/></s>
        <s sid="125">Although the apparent difference was statistically significant, it appears to be largely a function of the small SD and only represents an 18.5% difference between mean adduct levels in liver and lung.<CoreSc1 atype="GSC" type="Res" conceptID="Res7" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-28">
        <s sid="126"><xref class="xref-fig" href="#F5" rid="xref-fig-5-1">Figure 4</xref> shows the dose&#8211;response curves for THB-Gua formation in liver from mice and rats.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs6" novelty="None" advantage="None"/></s>
        <s sid="127">Adduct formation was almost linear in mice from 0 to 18 p.p.m. BD-diol.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs7" novelty="None" advantage="None"/></s>
        <s sid="128">The efficiency of adduct formation, defined as the amount of THB-Gua/ppm BD-diol, decreased as the exposure increased from 6 to 18 p.p.m. BD-diol.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs8" novelty="None" advantage="None"/></s>
        <s sid="129">Due to a technical error, data are unavailable for THB-Gua levels in mice exposed to 36 p.p.m. BD-diol.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs9" novelty="None" advantage="None"/></s>
        <s sid="130">In the rat, THB-Gua formation began to plateau at the higher exposure concentrations.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs10" novelty="None" advantage="None"/></s>
        <s sid="131">As was observed in the mouse, efficiency also decreased as the exposure level increased.<CoreSc1 atype="GSC" type="Res" conceptID="Res8" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Dosimetry of THB-Val</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-30">
        <s sid="132">The different stereoisomers of THB-Val are observed in the GC-MS/MS chromatogram from a female B6C3F1 mouse exposed to 36 p.p.m. BD-diol (<xref class="xref-fig" href="#F6" rid="xref-fig-6-1">Figure 5</xref>).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs11" novelty="None" advantage="None"/></s>
        <s sid="133">The two overlapping peaks correspond to the meso forms of the adduct, while the racemates coelute.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs12" novelty="None" advantage="None"/></s>
        <s sid="134">As with THB-Gua, a combination of isomers was used for quantification.<CoreSc1 atype="GSC" type="Met" conceptID="Met10" novelty="None" advantage="None"/></s>
        <s sid="135">The limit of detection (S/N &#8805; 3) was &#8764;200 amol of pure standard injected on column.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs13" novelty="None" advantage="None"/></s>
        <s sid="136">A representative calibration curve is provided in <xref class="xref-fig" href="#F7" rid="xref-fig-7-1">Figure 6</xref>.<CoreSc1 atype="GSC" type="Met" conceptID="Met11" novelty="None" advantage="None"/></s>
        <s sid="137">The smallest amount of adduct measured in globin from BD-diol exposed rodents was &#8764;40 fmol injected on column.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs14" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-33">
        <s sid="138"><xref class="xref-table" href="#T2" rid="xref-table-wrap-2-1">Table II</xref> presents the summary data for THB-Val formation in the BD-diol exposed mice and rats.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs15" novelty="None" advantage="None"/></s>
        <s sid="139">Comparisons of mean adduct levels between species were identical to what was observed for THB-Gua.<CoreSc1 atype="GSC" type="Res" conceptID="Res9" novelty="None" advantage="None"/></s>
        <s sid="140">Mice formed a greater amount of adduct/mg globin as demonstrated by a statistically significant difference in adduct levels between species at 6, 18 and 36 p.p.m. BD-diol.<CoreSc1 atype="GSC" type="Res" conceptID="Res10" novelty="None" advantage="None"/></s>
        <s sid="141">There was a 2.1-fold, 2.0-fold and 1.7-fold increase in the amount of THB-Val measured in mice and rat at 6, 18 and 36 p.p.m. BD-diol, respectively.<CoreSc1 atype="GSC" type="Res" conceptID="Res11" novelty="None" advantage="None"/></s>
        <s sid="142">In both species, there was a quantifiable level of adduct in globin from control animals.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs16" novelty="None" advantage="None"/></s>
        <s sid="143">Control mice had a 1.4-fold greater amount of adduct than control rats.<CoreSc1 atype="GSC" type="Res" conceptID="Res12" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-37">
        <s sid="144">A graphical presentation of the data (<xref class="xref-fig" href="#F8" rid="xref-fig-8-1">Figure 7</xref>) shows the dose&#8211;response in both species.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs17" novelty="None" advantage="None"/></s>
        <s sid="145">For both rats and mice, THB-Val formation began to plateau at the higher concentrations.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs18" novelty="None" advantage="None"/></s>
        <s sid="146">As was observed for THB-Gua, adduct efficiency decreased as the exposures increased.<CoreSc1 atype="GSC" type="Res" conceptID="Res13" novelty="None" advantage="None"/></s>
      </p>
    </SEC>
    <SEC>
      <TITLE>Discussion</TITLE>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-39">
        <s sid="147">When comparing the THB-adduct formation between species in the current study, we showed that mice exposed to BD-diol form greater amounts of both THB-Gua and THB-Val than rats.<CoreSc1 atype="GSC" type="Res" conceptID="Res14" novelty="None" advantage="None"/></s>
        <s sid="148">This species difference agrees with the existing data showing that mice form greater amounts of EB-diol derived DNA and hemoglobin adducts than rats exposed to a range of BD from 1 to 1250 p.p.m. (<xref class="xref-bibr" href="#ref-37" rid="xref-ref-37-2">37</xref>&#8211;<xref class="xref-bibr" href="#ref-42" rid="xref-ref-42-1">42</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res15" novelty="None" advantage="None"/></s>
        <s sid="149">The differences in THB adduct formation between mice and rats reflect species differences observed in the metabolism and toxic effects of BD.<CoreSc1 atype="GSC" type="Con" conceptID="Con3" novelty="None" advantage="None"/></s>
        <s sid="150">Several studies have demonstrated that mice have higher levels of BD metabolites than rats in tissues (<xref class="xref-bibr" href="#ref-43" rid="xref-ref-43-1">43</xref>,<xref class="xref-bibr" href="#ref-44" rid="xref-ref-44-1">44</xref>) and blood (<xref class="xref-bibr" href="#ref-43" rid="xref-ref-43-2">43</xref>,<xref class="xref-bibr" href="#ref-45" rid="xref-ref-45-1">45</xref>) following in vivo exposure to BD, as well as in perfusate following single-pass liver perfusion experiments (<xref class="xref-bibr" href="#ref-28" rid="xref-ref-28-2">28</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac23" novelty="None" advantage="None"/></s>
        <s sid="151">Hprt mutant frequencies in splenic T-cells of mice were consistently greater than those observed in rats concurrently exposed to BD (<xref class="xref-bibr" href="#ref-46" rid="xref-ref-46-1">46</xref>), EB (<xref class="xref-bibr" href="#ref-47" rid="xref-ref-47-1">47</xref>) and BD-diol (<xref class="xref-bibr" href="#ref-25" rid="xref-ref-25-6">25</xref>) and, as previously mentioned, the mouse is the most sensitive species in carcinogenicity studies (<xref class="xref-bibr" href="#ref-2" rid="xref-ref-2-3">2</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac24" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-40">
        <s sid="152">An evaluation of THB-Gua adducts showed virtually no differences between liver and lung for either species.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac25" novelty="None" advantage="None"/></s>
        <s sid="153">Koc et al. (<xref class="xref-bibr" href="#ref-37" rid="xref-ref-37-3">37</xref>) also observed similar THB-Gua levels in liver, lung as well as kidney from both rats and mice exposed to 20, 62.5 and 625 p.p.m. BD.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac26" novelty="None" advantage="None"/></s>
        <s sid="154">While THB-Gua levels in these tissues appear comparable, adduct levels in testis may be different.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac27" novelty="None" advantage="None"/></s>
        <s sid="155">Booth et al. (<xref class="xref-bibr" href="#ref-39" rid="xref-ref-39-2">39</xref>) showed that liver and lung have similar levels of THB-Gua, but the testis had lower levels in mice and rats exposed to 1, 5 or 20 p.p.m. BD.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac28" novelty="None" advantage="None"/></s>
        <s sid="156">On the other hand, mice exposed to 200 p.p.m. BD had similar levels of THB-Gua in liver, lung and testis (<xref class="xref-bibr" href="#ref-38" rid="xref-ref-38-2">38</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac29" novelty="None" advantage="None"/></s>
        <s sid="157">The differences between THB-Gua adduct levels in testis and the other tissues may be owing to the variations in DNA repair capacity at different BD exposure levels.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac30" novelty="None" advantage="None"/></s>
        <s sid="158">The activity of alkyladenine glycosylase (Aag), an enzyme involved in repairing N7-methylguanine adducts in mice (<xref class="xref-bibr" href="#ref-48" rid="xref-ref-48-1">48</xref>), is similar in liver, lung, and kidney but much higher in testis of male Aag<sup>+/+</sup> mice (<xref class="xref-bibr" href="#ref-49" rid="xref-ref-49-1">49</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac31" novelty="None" advantage="None"/></s>
        <s sid="159">This finding suggests that the testis has a greater ability to remove adducts via base excision repair at exposure levels that are unlikely to saturate DNA repair.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac32" novelty="None" advantage="None"/></s>
        <s sid="160">Since the results in our study show identical levels of THB-Gua between tissues with similar repair capabilities, it appears EB-diol is stable enough to circulate rapidly and evenly throughout the body as has been previously proposed (<xref class="xref-bibr" href="#ref-37" rid="xref-ref-37-4">37</xref>).<CoreSc1 atype="GSC" type="Con" conceptID="Con4" novelty="None" advantage="None"/></s>
        <s sid="161">However, to definitively determine the biological stability of EB-diol a method to quantify this metabolite needs to be developed.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot4" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-41">
        <s sid="162">The shape of the dose&#8211;response curves for THB-Gua and THB-Val are also noteworthy.<CoreSc1 atype="GSC" type="Res" conceptID="Res16" novelty="None" advantage="None"/></s>
        <s sid="163">Although no DNA adduct data for mice exposed to 36 p.p.m. BD-diol is available, the increase in THB adduct levels was similar when the BD-diol exposure increased from 6 to 18 p.p.m. THB-Gua in liver increased by 2.1-fold and THB-Val by 2.4-fold.<CoreSc1 atype="GSC" type="Res" conceptID="Res17" novelty="None" advantage="None"/></s>
        <s sid="164">Because of the extended dose&#8211;response data in the rat, the similarities in THB adduct formation are even more evident.<CoreSc1 atype="GSC" type="Res" conceptID="Res18" novelty="None" advantage="None"/></s>
        <s sid="165">The amount of adduct increased 2.1-fold for THB-Gua in liver and 2.5-fold for THB-Val when the exposure concentration was increased from 6 to 18 p.p.m. BD-diol.<CoreSc1 atype="GSC" type="Res" conceptID="Res19" novelty="None" advantage="None"/></s>
        <s sid="166">When the exposure was increased from 18 to 36 p.p.m. BD-diol, THB-Gua in the liver changed 1.6-fold and THB-Val changed 1.4-fold.<CoreSc1 atype="GSC" type="Res" conceptID="Res20" novelty="None" advantage="None"/></s>
        <s sid="167">Overall, at the exposure levels used in the current study THB adduct formation began to plateau at &#8764;18 p.p.m. BD-diol, indicative of metabolic saturation for EB-diol formation.<CoreSc1 atype="GSC" type="Con" conceptID="Con5" novelty="None" advantage="None"/></s>
        <s sid="168">This is not surprising since BD-diol clearance in female mice exposed to BD-diol is supralinear (<xref class="xref-bibr" href="#ref-25" rid="xref-ref-25-7">25</xref>), which also indicates metabolic saturation.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac33" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-42">
        <s sid="169">In order to compare our results with previous studies, it is important to understand the relevance of the selected BD-diol concentrations.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac34" novelty="None" advantage="None"/></s>
        <s sid="170">A single 6 h exposure to 18 p.p.m. BD-diol in female B6C3F1 mice or female F344 rats yielded an equivalent plasma concentration of BD-diol as a single 6 h exposure to 200 p.p.m. BD.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs19" novelty="None" advantage="None"/></s>
        <s sid="171">In female B6C3F1 mice, exposure to 36 p.p.m. BD-diol yielded &#8764;25% of the plasma concentration attained following exposure to 625 p.p.m. BD (<xref class="xref-bibr" href="#ref-25" rid="xref-ref-25-8">25</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res21" novelty="None" advantage="None"/></s>
        <s sid="172">Previous studies showed THB-Gua formation did not reach saturation in mice following exposures up to 1300 p.p.m. BD (<xref class="xref-bibr" href="#ref-37" rid="xref-ref-37-5">37</xref>,<xref class="xref-bibr" href="#ref-50" rid="xref-ref-50-1">50</xref>), while in rats THB-Gua formation began to plateau at BD exposures &gt;62.5 p.p.m. (<xref class="xref-bibr" href="#ref-37" rid="xref-ref-37-6">37</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac35" novelty="None" advantage="None"/></s>
        <s sid="173">Our results showed that THB-Gua formation in rats began to plateau &#8764;18 p.p.m. BD-diol, corresponding to a BD exposure of 200 p.p.m. We do not have dose&#8211;response data for THB-Gua formation in mouse.<CoreSc1 atype="GSC" type="Res" conceptID="Res22" novelty="None" advantage="None"/></s>
        <s sid="174">At lower concentrations our hemoglobin data were also consistent with the published results showing THB-Val formation did not reach saturation in male B6C3F1 mice and male Sprague&#8211;Dawley rats following 2 weeks of exposure to concentrations up to 20 p.p.m. BD (<xref class="xref-bibr" href="#ref-40" rid="xref-ref-40-2">40</xref>), or in female B6C3F1 mice or female F344 rats exposed to concentrations up to 62.5 p.p.m. BD for 4 weeks (<xref class="xref-bibr" href="#ref-41" rid="xref-ref-41-2">41</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res23" novelty="None" advantage="None"/></s>
        <s sid="175">At higher exposures THB-Val formation peaked in male Wistar rats at 200 p.p.m. BD (<xref class="xref-bibr" href="#ref-51" rid="xref-ref-51-1">51</xref>), corresponding to an exposure of 18 p.p.m. BD-diol.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac36" novelty="None" advantage="None"/></s>
        <s sid="176">Direct comparisons between BD and BD-diol are complicated, however, by the presence of different P450 substrates and their potential effects on metabolism.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac37" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-43">
        <s sid="177">Of great interest are the similar shaped dose&#8211;response curves observed for THB adduct formation and the induction of Hprt mutant frequency in splenic T-cells from mice (<xref class="xref-fig" href="#F9" rid="xref-fig-9-1">Figure 8a</xref>) and rats (<xref class="xref-fig" href="#F9" rid="xref-fig-9-2">Figures 8b</xref> and <xref class="xref-fig" href="#F10" rid="xref-fig-10-1">9</xref>) exposed to BD-diol.<CoreSc1 atype="GSC" type="Res" conceptID="Res24" novelty="None" advantage="None"/></s>
        <s sid="178">These similarities suggest that THB adducts are good quantitative indicators of EB-diol formation and its resulting splenic T-cell mutagenicity at the Hprt locus in rodents exposed to BD-diol.<CoreSc1 atype="GSC" type="Con" conceptID="Con6" novelty="None" advantage="None"/></s>
        <s sid="179">A similar conclusion was given by Meng et al. (<xref class="xref-bibr" href="#ref-52" rid="xref-ref-52-1">52</xref>) who found that THB-Gua formation correlated with Hprt mutation frequency in rodents exposed to 0, 6.25, 62.5 and 625 p.p.m. BD.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac38" novelty="None" advantage="None"/></s>
        <s sid="180">Based on both the current study and the previous work, it appears that EB-diol plays a significant role in BD-diol and BD associated mutagenicity.<CoreSc1 atype="GSC" type="Con" conceptID="Con7" novelty="None" advantage="None"/></s>
        <s sid="181">It is not likely that THB-Gua is actually causing the Hprt mutations since N-7 alkylguanine adducts are not promutagenic.<CoreSc1 atype="GSC" type="Con" conceptID="Con8" novelty="None" advantage="None"/></s>
        <s sid="182">Other minor promutagenic THB adducts may, however, be responsible.<CoreSc1 atype="GSC" type="Con" conceptID="Con9" novelty="None" advantage="None"/></s>
        <s sid="183">This will require additional studies, as these adducts have not been quantified.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot5" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-46">
        <s sid="184">In summary, this is the first description of THB adduct dosimetry in rodents exposed to BD-diol.<CoreSc1 atype="GSC" type="Con" conceptID="Con10" novelty="None" advantage="None"/></s>
        <s sid="185">The data agree with the species differences observed in BD metabolism, mutagenicity and carcinogenicity.<CoreSc1 atype="GSC" type="Con" conceptID="Con11" novelty="None" advantage="None"/></s>
        <s sid="186">More importantly, our data show that THB adducts arising from EB-diol may be good quantitative indicators of mutagenicity.<CoreSc1 atype="GSC" type="Con" conceptID="Con12" novelty="None" advantage="None"/></s>
        <s sid="187">While our results suggest that EB-diol contributes to BD-diol associated mutagenicity, it remains necessary to determine the contributions made by HMVK.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot6" novelty="None" advantage="None"/></s>
        <s sid="188">Sprague and Elfarra (<xref class="xref-bibr" href="#ref-22" rid="xref-ref-22-2">22</xref>) showed that as the dose was increased the percentage of BD-diol metabolized to HMVK-derived mercapturic acid decreased.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac39" novelty="None" advantage="None"/></s>
        <s sid="189">The authors interpret this as an indication of metabolic saturation.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac40" novelty="None" advantage="None"/></s>
        <s sid="190">However, the formation of HMVK-derived mercapturic acid metabolites appears to be approximately linear up to doses of 1420 &#956;mol/kg or 125 mg/kg, in male B6C3F1 mice and male Sprague&#8211;Dawley rats.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac41" novelty="None" advantage="None"/></s>
        <s sid="191">Following intraperitoneal injection of 100 mg/kg BD-diol, a plasma concentration &gt;100 &#956;g BD-diol/ml in male B6C3F1 mice was observed (<xref class="xref-bibr" href="#ref-16" rid="xref-ref-16-2">16</xref>) while inhalation of 36 p.p.m. BD-diol for 6 h, the highest concentration used in our current study, produced a plasma concentration of &#8764;2.5 &#956;g BD-diol/ml in female B6C3F1 mice.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac42" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Mot" conceptID="Mot7" novelty="None" advantage="None"/></s>
        <s sid="192">Therefore, it appears as if HMVK formation, indicated by HMVK-derived mercapturic acid formation, is linear at plasma BD-diol concentrations more than 40&#215; greater than that evaluated in the current study.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac43" novelty="None" advantage="None"/></s>
        <s sid="193">Because Walker et al. (<xref class="xref-bibr" href="#ref-25" rid="xref-ref-25-12">25</xref>) observed a plateau in the induction of Hprt mutations at concentrations considerably lower than where HMVK saturation would occur, it is unlikely that HMVK is as important as EB-diol in BD-diol associated mutagenicity.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac44" novelty="None" advantage="None"/></s>
        <s sid="194">However, empirical evidence is needed to prove this hypothesis.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot8" novelty="None" advantage="None"/></s>
        <s sid="195">While the potential mutagenicity of HMVK is yet to be determined, it is likely that EB-diol is responsible, at least in part, for the mutagenicity associated with BD-diol.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot9" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Con" conceptID="Con13" novelty="None" advantage="None"/></s>
      </p>
    </SEC>
    <SEC>
      <TITLE>Acknowledgments</TITLE>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-47">
        <s sid="196">This research was funded by the HEI (99&#8211;5), the NIEHS (R01-ES012689, R42-ES11746, and P30-ES10126), and the NCI (P30-CA16086).</s>
        <s sid="197">Support was also provided by an individual NRSA postdoctoral fellowship from the NIEHS (F32-ES012357&#8211;01).</s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-48">
        <s sid="198">Conflict of Interest Statement: The contents of this manuscript are solely the responsibility of the authors and do not necessarily represent the official views of the NIEHS.</s>
      </p>
    </SEC>
    <SEC>
      <TITLE>References</TITLE>
    </SEC>
  </BODY>
</PAPER>